Abstract
It was recently reported that RUNX3 gene expression is significantly downregulated in human gastric cancer cells due to hypermethylation of its promoter region or hemizygous deletion (Cell, 109, 2002). To verify the genetic alterations and methylation status of the RUNX3 gene in colorectal carcinogenesis, we analysed for mutations, loss of heterozygosity (LOH), and RUNX3 gene promoter hypermethylation, in 32 colorectal cancer cell lines. RT–PCR analysis showed undetectable or low RUNX3 expression in 16 cell lines, and no mutations were found in the RUNX3 gene by PCR-SSCP analysis. Of these 16 cell lines, hypermethylation of the RUNX3 promoter was confirmed in 12. The following observations were made: (i) RUNX3 was re-expressed after 5-aza-2′-deoxycytidine treatment, (ii) the RUNX3 promoter was found to be methylated by MS-PCR, and (iii) hypermethylation of the RUNX3 promoter was confirmed by direct sequencing analysis after sodium bisulfite modification in the above 12 cell lines. RUNX3 was neither methylated nor expressed in four cell lines. Of these four, microsatellite instability (MSI) at the RUNX3 locus was found in three, SNU-61 (D1S246), SNU-769A, and SNU-769B (D1S199). This study suggests that transcriptional repression of RUNX3 is caused by promoter hypermethylation of the RUNX3 CpG island in colorectal cancer cell lines, and the results of these experiments may contribute to an understanding of the role of RUNX3 inactivation in the pathogenesis of colorectal cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D, Lotem J, Ben-Asher E, Lancet D, Levanon D and Groner Y . (2001). Gene, 279, 221–232.
Di Vinci A, Infusini E, Nigro S, Monaco R and Giaretti W . (1998a). Cancer, 83, 415–422.
Di Vinci A, Infusini E, Peveri C, Sciutto A, Geido E, Risio M, Rossini FP and Giaretti W . (1998b). Int. J. Cancer, 75, 45–50.
Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB and Herman JG . (2001). Hum. Mol. Genet., 10, 3001–3007.
Ezaki T, Yanagisawa A, Ohta K, Aiso S, Watanabe M, Hibi T, Kato Y, Nakajima T, Ariyama T, Inazawa J, Nakamura Y and Horii A . (1996). Br. J. Cancer, 73, 424–428.
Guo WH, Weng LQ, Ito K, Chen LF, Nakanishi H, Tatematsu M and Ito Y . (2002). Oncogene, 21, 8351–8355.
Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.
Hung J, Kishimoto Y, Sugio K, Virmani A, Mclntire DD, Minna JD and Gazdar AF . (1995). J. Am. Med. Assoc., 273, 558–563.
Ito Y and Miyazono K . (2003). Curr. Opin. Genet. Dev., 13, 43–47.
Ku JL, Yoon KA, Kim DY and Park JG . (1999). Eur. J. Cancer, 35, 1724–1729.
Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB and Park JG . (2002). Br. J. Cancer, 87, 187–193.
Lee KS, Hong SH and Bae SC . (2002). Oncogene, 21, 7156–7163.
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue KI, Chi XZ, Lee KY, Nomura S, Lee CW, Ban SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y . (2002). Cell, 109, 113–124.
Melki JR, Vincent PC, Brown RD and Clark SJ . (2000). Blood, 95, 3208–3213.
Nam S, Jin YH, Li QL, Lee KY, Jeong GB, Ito Y, Lee JH and Bae SC . (2002). Mol. Cell. Biol., 22, 547–554.
Ogunbiyi OA, Goodfellow PJ, Gagliardi G, Swanson PE, Birnbaum EH, Fleshman JW, Kodner IJ and Moley JF . (1997). Gastroenterology, 113, 761–766.
Oh JW, Ku JL, Yoon KA, Kwon HJ, Kim WH, Park HS, Yeo KS, Song SY, Chung JK and Park JG . (1999). Int. J. Cancer, 81, 902–910.
Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE and Gazdar AF . (1987). Cancer Res., 47, 6710–6718.
Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG and Esteller M . (2003). Cancer Res., 63, 1114–1121.
Praml C, Finke LH, Herfarth C, Schlag P, Schwab M and Amler L . (1995). Oncogene, 11, 1357–1362.
Rini D and Calabi F . (2001). Gene, 273, 13–22.
Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA and Plass C . (2001). Hum. Mol. Genet., 10, 1413–1419.
Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK and Bang YJ . (2001). Cancer Res., 61, 4628–4635.
Suh ER, Ha CS, Rankin EB, Toyota M and Traber PG . (2002). J. Biol. Chem., 277, 35759–35800.
Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T and Miyaki M . (1993). Oncogene, 8, 2253–2258.
Trojan J, Brieger A, Raedle J, Esteller M and Zeuzem S . (2000). Gut, 47, 272–276.
van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij AF and Herman JG . (2002). Oncogene, 21, 3792–3795.
Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T and Kakudo K . (2002). Clin. Cancer Res., 8, 2890–2893.
Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and Minna JD . (2001). Cancer Res., 61, 3581–3585.
Acknowledgements
This work was supported in part by the 2002 BK21 Project for Medicine, Dentistry, and Pharmacy and in part by the Basic Research Program (R01-2003-000-10543-0) of the Korea Science & Engineering Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ku, JL., Kang, SB., Shin, YK. et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23, 6736–6742 (2004). https://doi.org/10.1038/sj.onc.1207731
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207731
Keywords
This article is cited by
-
Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications
Oncogene (2021)
-
Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India
Cancer Cell International (2020)
-
RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer
Oncogene (2019)
-
DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition
Cancer Cell International (2018)
-
STAT3 signaling contributes to the high effector activities of interleukin‐15‐derived dendritic cells
Immunology & Cell Biology (2015)